Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
10
×
san francisco blog main
10
×
startups
10
×
biotech
boston blog main
boston top stories
deals
new york blog main
san diego blog main
new york top stories
san diego top stories
san francisco top stories
cancer
vc
raleigh-durham blog main
raleigh-durham top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
ipo
national
novartis
seattle blog main
seattle top stories
texas blog main
texas top stories
aducanumab
alzheimer's disease
asklepios biopharmaceutical
biogen
bristol-myers squibb
cancer immunotherapy
What
new
10
×
medicines
drug
bio
biotech
drugs
roundup
startup
cancer
developing
earlier
million
technology
therapeutics
today
venture
year
activity
adds
advance
aim
aiming
aims
alliance
ambys
approach
approval
approvals
areas
athena
bails
based
big
bigger
biogen
biogen’s
biologic
biology
biopharmaceutical
biosciences
Language
unset
Current search:
new
×
startups
×
" san francisco blog main "
×
" national top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
After 33 Exits in 5 Years, WI Seeks “More and Bigger” Startup Deals
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs